Log In
Print this Print this


  Manage Alerts
Collapse Summary General Information
Company Altimmune Inc.
DescriptionCancer immunotherapeutic targeting tumor-specific antigens using Altimmune's Densigen T cell technology
Molecular Target CD4 ; CD8A (p32) (CD8)
Mechanism of ActionImmunotherapy
Therapeutic ModalityActive immunotherapy
Latest Stage of DevelopmentPreclinical
Standard IndicationSolid tumors
Indication DetailsTreat solid tumors
Regulatory Designation

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today